Pfizer Reports Long-Term Survival Benefit for BRAFTOVI + MEKTOVI in BRAF V600E-Mutant NSCLC
I'm PortAI, I can summarize articles.
Pfizer Inc. has reported updated results from the Phase 2 PHAROS trial for BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) in treating metastatic non-small cell lung cancer with the BRAF V600E mutation. The trial showed a median overall survival of 47.6 months for treatment-naïve patients and 22.7 months for previously treated patients, with four-year survival rates of 49% and 31%, respectively. Common adverse events included nausea and fatigue. Results will be presented at the 2025 ESMO Congress and published in the Journal of Clinical Oncology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments